DSTNP2: A Promising Drug Target / Biomarker (G171220)

Target Name: DSTNP2

NCBI ID: G171220

DSTNP2

Other Name(s): DSTN pseudogene 2

DSTNP2: A Promising Drug Target / Biomarker

Drug targets (DGs) are important molecules that are targeted by drugs to modulate their biological activity. One of the most promising DGs in recent years is the neurotransmitter dopamine (D2) receptor, which plays a crucial role in various physiological processes in the brain. The D2 receptor is a G protein-coupled receptor (GPCR), and its function is to regulate the release of neurotransmitters, including dopamine, in the brain. DSTNP2, a novel N-methyl-D-aspartate (NMDA) receptor antagonist, has been identified as a potential drug target for the treatment of various neurological disorders.

DSTNP2: Structure and Function

DSTNP2 is a short non-coding RNA molecule that is predominantly expressed in the brain. It is a member of the DNMTBP family, which includes several other non-coding RNAs that play important roles in the regulation of DNA methylation. DSTNP2 is characterized by a unique structure, which consists of a single exon and a single RNA molecule. It has a calculated molecular weight of 18.8 kDa and a predicted localization in the brain.

DSTNP2 functions as an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptors are involved in various physiological processes, including neurotransmission, learning, and synaptic plasticity. They are also involved in the regulation of pain perception and anxiety. DSTNP2 is specifically designed to inhibit the activity of NMDA receptors, which would lead to the reduction of neurotransmitter release and improve the therapeutic outcomes in diseases associated with neurotransmission disorders.

DSTNP2 has been shown to be involved in various physiological processes in the brain, including the regulation of neurotransmission, learning, and synaptic plasticity. For instance, studies have shown that DSTNP2 is involved in the regulation of neurotransmitter release from postsynaptic neurons, which is critical for the modulation of neural circuits. DSTNP2 has also been shown to play a role in the regulation of learning and memory processes, as well as the modulation of synaptic plasticity.

DSTNP2 Interactions with Other Receptors

DSTNP2 has been shown to interact with several other receptors, including GPCR, GPR, and TrkB. The interaction of DSTNP2 with GPCR receptors is thought to play a role in the modulation of neurotransmission by GPCRs. For instance, DSTNP2 has been shown to interact with the GPCR receptor B3, which is involved in the regulation of anxiety and depression. The interaction between DSTNP2 and B3 has been shown to modulate the activity of B3, leading to the reduction of neurotransmission.

DSTNP2 Interactions with Other Non-Code RNAs

DSTNP2 has also been shown to interact with several other non-code RNAs, including DNMTBP2, DNMTB3, and DNMTBP3. The interaction of DSTNP2 with these non-code RNAs is thought to play a role in the regulation of DNA methylation. For instance, DSTNP2 has been shown to interact with DNMTBP2, which is a critical regulator of DNA methylation. The interaction between DSTNP2 and DNMTBP2 has been shown to modulate the activity of DNMTBP2, leading to the regulation of DNA methylation.

DSTNP2 Theoretical Model

The theoretical model of DSTNP2 is based on the idea of a simple RNA molecule that functions as an NMDA receptor antagonist. The molecule has a single exon and a single RNA molecule, and it is primarily expressed in the brain. The molecule has been shown to interact with several other molecules, including GPCR, GPR, and TrkB. The interaction between DSTNP2 and GPCR receptors is thought to play a role in the modulation of neurotransmission by GPCRs.

Conclusion

DSTNP2 is a novel N-methyl-D-aspartate (NMDA) receptor antagonist that has been identified as a potential drug target for the treatment of various neurological disorders. Its unique structure and function, as well as its interaction with several other receptors, including GPCR, GPR, and TrkB, make it an attractive target for the development of new therapeutic strategies. Further research is needed to fully understand the molecular mechanisms of DSTNP2 and its potential as a therapeutic drug.

Protein Name: DSTN Pseudogene 2

The "DSTNP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DSTNP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets